GSK (LON:GSK) Receives Neutral Rating from UBS Group

GSK (LON:GSK)‘s stock had its “neutral” rating restated by research analysts at UBS Group in a report released on Friday, MarketBeat Ratings reports. They currently have a GBX 1,940 price target on the stock. UBS Group’s target price suggests a potential upside of 7.51% from the company’s current price.

Several other research analysts have also issued reports on GSK. Berenberg Bank increased their price objective on GSK from GBX 1,600 to GBX 1,660 and gave the stock a “hold” rating in a research note on Monday, November 24th. Shore Capital reiterated a “buy” rating on shares of GSK in a research report on Thursday, January 8th. JPMorgan Chase & Co. reissued an “underweight” rating on shares of GSK in a report on Wednesday, January 7th. Deutsche Bank Aktiengesellschaft upped their price objective on shares of GSK from GBX 1,600 to GBX 1,675 and gave the stock a “hold” rating in a research note on Thursday, January 15th. Finally, Jefferies Financial Group reissued a “buy” rating and issued a GBX 2,100 target price on shares of GSK in a report on Wednesday, January 7th. Two analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of GBX 1,829.17.

GSK Price Performance

Shares of GSK opened at GBX 1,804.50 on Friday. The stock has a market cap of £72.80 billion, a price-to-earnings ratio of 13.57, a P/E/G ratio of 1.24 and a beta of 0.31. The company has a quick ratio of 0.73, a current ratio of 0.81 and a debt-to-equity ratio of 114.64. GSK has a 12 month low of GBX 1,242.50 and a 12 month high of GBX 1,909.73. The company has a 50-day moving average price of GBX 1,817.31 and a two-hundred day moving average price of GBX 1,627.41.

GSK (LON:GSK) last released its quarterly earnings data on Wednesday, October 29th. The company reported GBX 55 earnings per share for the quarter. GSK had a return on equity of 18.08% and a net margin of 8.02%. Equities analysts predict that GSK will post 175.980975 EPS for the current fiscal year.

Insider Buying and Selling at GSK

In other GSK news, insider Jonathan Symonds bought 1,650 shares of the company’s stock in a transaction on Monday, December 22nd. The stock was bought at an average price of GBX 1,810 per share, for a total transaction of £29,865. Also, insider Wendy Becker bought 441 shares of GSK stock in a transaction on Friday, December 19th. The shares were bought at an average price of GBX 1,809 per share, for a total transaction of £7,977.69. Insiders own 0.20% of the company’s stock.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.